» Articles » PMID: 39339876

Production and Characterization of Self-Assembled Virus-like Particles Comprising Capsid Proteins from Genotypes 3 and 4 Hepatitis E Virus (HEV) and Rabbit HEV Expressed in

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2024 Sep 28
PMID 39339876
Authors
Affiliations
Soon will be listed here.
Abstract

The zoonotic transmission of hepatitis E virus (HEV) genotypes 3 (HEV-3) and 4 (HEV-4), and rabbit HEV (HEV-3ra) has been documented. Vaccination against HEV infection depends on the capsid (open reading frame 2, ORF2) protein, which is highly immunogenic and elicits effective virus-neutralizing antibodies. () is utilized as an effective system for producing HEV-like particles (VLPs). However, research on the production of ORF2 proteins from these HEV genotypes in E. coli to form VLPs has been modest. In this study, we constructed 21 recombinant plasmids expressing various N-terminally and C-terminally truncated HEV ORF2 proteins for HEV-3, HEV-3ra, and HEV-4 in . We successfully obtained nine HEV-3, two HEV-3ra, and ten HEV-4 ORF2 proteins, which were primarily localized in inclusion bodies. These proteins were solubilized in 4 M urea, filtered, and subjected to gel filtration. Results revealed that six HEV-3, one HEV-3ra, and two HEV-4 truncated proteins could assemble into VLPs. The purified VLPs displayed molecular weights ranging from 27.1 to 63.4 kDa and demonstrated high purity (74.7-95.3%), as assessed by bioanalyzer, with yields of 13.9-89.6 mg per 100 mL of TB medium. Immunoelectron microscopy confirmed the origin of these VLPs from HEV ORF2. Antigenicity testing indicated that these VLPs possess characteristic HEV antigenicity. Evaluation of immunogenicity in Balb/cAJcl mice revealed robust anti-HEV IgG responses, highlighting the potential of these VLPs as immunogens. These findings suggest that the generated HEV VLPs of different genotypes could serve as valuable tools for HEV research and vaccine development.

Citing Articles

Descriptive Comparative Transcriptomic Analysis of Genotype IV SHEV ORF3-Expressing HepG2 Cells.

Jiao H, Meng C, Jiao F, Zhou G, Wang L, Wu S Microorganisms. 2025; 13(2).

PMID: 40005777 PMC: 11858143. DOI: 10.3390/microorganisms13020412.

References
1.
Hadj Hassine I, Mhadheb M, Almalki M, Gharbi J . Virus-like particles as powerful vaccination strategy against human viruses. Rev Med Virol. 2023; 34(1):e2498. DOI: 10.1002/rmv.2498. View

2.
Nagashima S, Takahashi M, Kobayashi T, Nishizawa T, Nishiyama T, Primadharsini P . Characterization of the Quasi-Enveloped Hepatitis E Virus Particles Released by the Cellular Exosomal Pathway. J Virol. 2017; 91(22). PMC: 5660490. DOI: 10.1128/JVI.00822-17. View

3.
Li S, Zhao Q, Wu T, Chen S, Zhang J, Xia N . The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015; 11(4):908-14. PMC: 4514148. DOI: 10.1080/21645515.2015.1008870. View

4.
Schofield D, Glamann J, Emerson S, Purcell R . Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol. 2000; 74(12):5548-55. PMC: 112041. DOI: 10.1128/jvi.74.12.5548-5555.2000. View

5.
Tanaka T, Takahashi M, Takahashi H, Ichiyama K, Hoshino Y, Nagashima S . Development and characterization of a genotype 4 hepatitis E virus cell culture system using a HE-JF5/15F strain recovered from a fulminant hepatitis patient. J Clin Microbiol. 2009; 47(6):1906-10. PMC: 2691090. DOI: 10.1128/JCM.00629-09. View